Resources for Patients and their Families

USS Haraden (DD-585)

The USS Haraden (DD-585) was commissioned by the U.S. Navy during World War II, and remained on the Naval Register until the 1970s. She was named for Lieutenant Jonathan Haraden, who served in the American Revolutionary War. Haraden was laid down as a Fletcher-class destroyer.


Haraden was laid down by the Boston Navy Yard in November 1942, launched in March, and commissioned in September 1943 with Commander H.C. Allen, Jr., in command. With a crew complement of 273, Haraden was 376 feet, five inches in length and armed with five 5-inch anti-aircraft guns, four 1.1-inch anti-aircraft guns, four 20-millimeter anti-aircraft guns, and ten 21-inch torpedo tubes.

Naval History

Haraden was deployed with aircraft carrier USS Intrepid in the Pacific in November 1943. In December, the destroyer joined the Northern Support Group and operated as an escort for troop transports prior to the invasion of the Marshall Islands. During this deployment, Haraden destroyed an ammunition dump on Ennagannet Island, and also conducted anti-submarine patrol. Haraden mostly remained in the Marshall Islands until late February 1944.

Haraden spent a brief time at Pearl Harbor in March and then returned to the Marshall Islands with fuel carriers, and continued anti-submarine patrols and fire support. She was then assigned as an aircraft carrier escort out of Pearl Harbor to the Mariana Islands during operations there. In October, Haraden was assigned to escorting troop transport vessels to the Philippines, where she remained as an anti-aircraft screen and escort. During this deployment, Haraden participated in the invasion of Mindoro, where she was severely damaged by a kamikaze plane. This killed 14 crew members, and wounded 24 more. The destroyer underwent repairs at Puget Sound Navy Yard in January 1945 and left San Francisco in April.

Haraden was assigned to escort duty in the western Pacific, and operated off the Chinese coast after Japan surrendered at the end of the war. In September, Haraden supported the landings of occupation forces in various locations in Japan. The destroyer arrived back in the United States in January 1946, and was decommissioned at San Diego in July. Haraden remained in reserve until struck from the Navy list in November 1972, and was sunk in November 1973.

Asbestos Risk on the USS Haraden (DD-585)

Many navy veterans that served on the USS Haraden were regularly exposed to ACMs (asbestos-containing materials). Some occupations were prone to higher levels of asbestos exposure, however, including engine mechanics, those who worked in the pump room and those responsible for tending fire in the boiler room. When inhaled or ingested, tiny asbestos fibers can become lodged in the lungs and eventually result in the development of pleural mesothelioma. An extraordinary amount of asbestos-containing material could also be found in shipyards and, of course, on the ships docked in them causing many shipyard workers to suffer from asbestos exposure as well.

After Haraden experienced battle damage, repair crews and dock workers alike would be exposed to high levels of asbestos from the damaged sections of the ship. Even those not working in damage control had some exposure, however, as insulation made from asbestos was used to cover the steam pipes which ran through the entire ship. Sleeping quarters and the mess hall were other areas where high concentrations of asbestos could be found.

Exposure to asbestos is an established cause of a number of other serious conditions including asbestosis and lung cancer. A mesothelioma lawyer can help with options for former Navy personnel who discover they have mesothelioma.



Haze Gray & Underway. Dictionary of American Naval Fighting Ships. DD-585.
( Retrieved 25 January 2011.

NavSource Naval History. USS Haraden (DD-585).
( Retrieved 25 January 2011.

Mesothelioma Cancer Alliance Blog



MCA Observes World Day for Safety and Health at Work

Life After Cancer: What Survivorship Means for These Individuals

Baylor Mesothelioma Doctor Has High Hopes for Preoperative Immunotherapy